Impact of Brokerage Rating on Sarepta Therapeutics, Inc.(SRPT)

Many Sarepta Therapeutics, Inc.(SRPT) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Sarepta Therapeutics Inc was Reiterated by Morgan Stanley on Jan 4, 2017 to Equal-Weight, Lowers Price Target to $ 33 from a previous price target of $53 .Sarepta Therapeutics Inc was Initiated by JP Morgan on Dec 22, 2016 to Overweight, Price Target of the shares are set at $40.Sarepta Therapeutics Inc was Initiated by Goldman to Neutral on Dec 20, 2016. Sarepta Therapeutics Inc was Reiterated by RBC Capital Mkts on Dec 16, 2016 to Outperform, Lowers Price Target to $ 98 from a previous price target of $106 .Sarepta Therapeutics Inc was Reiterated by Jefferies on Dec 14, 2016 to Hold, Lowers Price Target to $ 32 from a previous price target of $46 .

Company has reported several Insider transactions to the SEC, on Oct 19, 2016, Sandesh Mahatme (Senior Vice President, CFO) sold 30,000 shares at 50.08 per share price.On Sep 30, 2016, Shamim Ruff (SVP, Regulatory Affairs & Qual) sold 7,311 shares at 60.00 per share price.On Sep 26, 2016, Edward M. Md Kaye (President, CEO & CMO) sold 40,179 shares at 60.00 per share price.

Sarepta Therapeutics Inc Last issued its quarterly earnings results on Oct 27, 2016. The company reported $-0.95 EPS for the quarter, beating the analyst consensus estimate by $ 0.33. Analyst had a consensus of $-1.28.During the same quarter in the previous year, the company posted $-1.11 EPS.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.71 by 14 Brokerage Firm. 8 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 4 Brokerage Firms have advised hold.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): The mean estimate for the short term price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands at $61.27 according to 15 Analysts. The higher price target estimate for the stock has been calculated at $102 while the lower price target estimate is at $32.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose 2.17% or 0.6 points on Tuesday and made its way into the gainers of the day. After trading began at $27.8 the stock was seen hitting $28.95 as a peak level and $27.75 as the lowest level. The stock ended up at $28.27. The daily volume was measured at 1,922,542 shares. The 52-week high of the share price is $63.73 and the 52-week low is $8. The company has a market cap of $1,543 million.

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Companys diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.

Sarepta

For any feedback and suggestions contact author at Saint.Larson@thefoundersdaily.com

Add Comment